Andrew Joseph , 2025-04-17 15:27:00
Contents
GSK’s blood cancer drug Blenrep won regulatory approval in the U.K. on Thursday, marking the medicine’s return to the market after it was withdrawn several years ago.
The drug, which treats multiple myeloma, will be used in combination with other medicines in patients whose cancer has resurged after an earlier line of treatment, under the approval from the Medicines and Healthcare products Regulatory Agency.
Blenrep had previously been approved in the U.S., European Union, U.K., and other countries, but GSK pulled it from the market in 2022 after the drug failed in a study meant to confirm its benefit.
This article is exclusive to STAT+ subscribers
Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.
Already have an account? Log in
To read the rest of this story subscribe to STAT+.